Management of voriconazole hepatotoxicity in a lung transplant patient. - Archive ouverte HAL Access content directly
Journal Articles Transplant Infectious Disease Year : 2011

Management of voriconazole hepatotoxicity in a lung transplant patient.

(1) , (2) , (3) , (4) , (4) , (4, 5)
1
2
3
4
5

Abstract

Lung allograft airway colonization by Aspergillus species is common among lung transplant recipients. We report the case of a 46-year-old female lung transplant outpatient diagnosed with persistent pulmonary Aspergillus colonization (>50 colonies of Aspergillus terreus) 3 months after lung transplantation. Oral voriconazole 200 mg twice a day (b.i.d) was initiated shortly after diagnosis. Two days after voriconazole initiation, alkaline phosphatase (ALP), alanine transaminase (ALT), and aspartate transaminase (AST) were normal or slightly elevated (79, 37, and 21 UI/L, respectively). Ten days after the first voriconazole administration, these values started to increase. Maximum levels were reached after 20 days for ALP (369 UI/L) and at around 30 days for ALT and AST (223 and 188 UI/L, respectively). Instead of discontinuing antifungal therapy, it was decided to reduce the voriconazole dose to 100 mg b.i.d. This asymptomatic progressive cholestatic hepatitis resolved, and 10 days after dose reduction ALP, ALT, AST were at 136, 53, and 28 UI/L, respectively. Finally, therapeutic drug monitoring revealed adequate voriconazole plasma trough concentrations (0.98 mg/L) 30 days after dose reduction and no more colonies of Aspergillus were observed. Voriconazole-induced hepatotoxicity is a well known dose-dependent adverse drug reaction. This experience confirms the appropriateness of voriconazole dose reduction instead of therapy interruption in dose-dependent moderate liver toxicity. Voriconazole therapeutic drug monitoring before and after dose reduction may help to avoid drug accumulation and inappropriately low drug exposure, respectively.

Dates and versions

inserm-00696413 , version 1 (15-05-2012)

Identifiers

Cite

Stéphanie Belaiche, Matthieu Roustit, Pierrick Bedouch, Sébastien Quetant, Christel Saint-Raymond, et al.. Management of voriconazole hepatotoxicity in a lung transplant patient.. Transplant Infectious Disease, 2011, 13 (3), pp.309-11. ⟨10.1111/j.1399-3062.2010.00590.x⟩. ⟨inserm-00696413⟩
906 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More